CA2225796C - Novel formulation for peptide release - Google Patents
Novel formulation for peptide release Download PDFInfo
- Publication number
- CA2225796C CA2225796C CA2225796A CA2225796A CA2225796C CA 2225796 C CA2225796 C CA 2225796C CA 2225796 A CA2225796 A CA 2225796A CA 2225796 A CA2225796 A CA 2225796A CA 2225796 C CA2225796 C CA 2225796C
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- deslorelin
- disease
- condition
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 238000009472 formulation Methods 0.000 title claims abstract description 57
- 108090000765 processed proteins & peptides Proteins 0.000 title description 9
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims abstract description 35
- 108700025485 deslorelin Proteins 0.000 claims abstract description 35
- 229960005408 deslorelin Drugs 0.000 claims abstract description 35
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 32
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 230000001629 suppression Effects 0.000 claims abstract description 16
- 229960003604 testosterone Drugs 0.000 claims abstract description 16
- 230000001850 reproductive effect Effects 0.000 claims abstract description 13
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
- 230000009286 beneficial effect Effects 0.000 claims abstract description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 229960005309 estradiol Drugs 0.000 claims abstract description 8
- 229930182833 estradiol Natural products 0.000 claims abstract description 8
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 239000002953 phosphate buffered saline Substances 0.000 claims abstract description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims abstract description 6
- 241000282326 Felis catus Species 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims description 22
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 13
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 13
- 229940067606 lecithin Drugs 0.000 claims description 13
- 239000000787 lecithin Substances 0.000 claims description 13
- 235000010445 lecithin Nutrition 0.000 claims description 13
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 7
- 201000009273 Endometriosis Diseases 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims description 5
- 201000004458 Myoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 230000002611 ovarian Effects 0.000 claims description 5
- 208000006155 precocious puberty Diseases 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 4
- 201000000484 premenstrual tension Diseases 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
- 210000002307 prostate Anatomy 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 24
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 17
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 17
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 17
- 230000012173 estrus Effects 0.000 description 12
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 238000002513 implantation Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000000186 progesterone Substances 0.000 description 5
- 229960003387 progesterone Drugs 0.000 description 5
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- -1 deslorelin Chemical class 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 206010043298 Testicular atrophy Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000010788 atrophy of testis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004368 gonadotroph Anatomy 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001719 neurosecretory cell Anatomy 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 150000002943 palmitic acids Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010539 reproductive behavior Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 231100001044 testicular atrophy Toxicity 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN3667A AUPN366795A0 (en) | 1995-06-20 | 1995-06-20 | Formulation for preventing reproductive function |
| AUPN3667 | 1995-06-20 | ||
| PCT/AU1996/000370 WO1997000693A1 (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2225796A1 CA2225796A1 (en) | 1997-01-09 |
| CA2225796C true CA2225796C (en) | 2011-09-20 |
Family
ID=3788008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2225796A Expired - Lifetime CA2225796C (en) | 1995-06-20 | 1996-06-20 | Novel formulation for peptide release |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5925619A (enExample) |
| EP (1) | EP0871467B1 (enExample) |
| JP (1) | JP4016133B2 (enExample) |
| CN (1) | CN1145496C (enExample) |
| AT (1) | ATE223726T1 (enExample) |
| AU (2) | AUPN366795A0 (enExample) |
| CA (1) | CA2225796C (enExample) |
| DE (2) | DE69623652T2 (enExample) |
| DK (1) | DK0871467T3 (enExample) |
| ES (1) | ES2182983T3 (enExample) |
| FR (1) | FR08C0001I2 (enExample) |
| NL (1) | NL300330I2 (enExample) |
| NZ (1) | NZ309697A (enExample) |
| PT (1) | PT871467E (enExample) |
| SI (1) | SI0871467T1 (enExample) |
| WO (1) | WO1997000693A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
| CA2264562C (en) | 1996-08-30 | 2012-01-03 | Peptech Limited | Sustained peptide-release formulation |
| WO2000004897A1 (en) * | 1998-07-20 | 2000-02-03 | Peptech Limited | Bioimplant formulation |
| US8052982B2 (en) * | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| US6211221B1 (en) * | 1999-04-05 | 2001-04-03 | Johnny W. Peterson | Dietary supplement containing histidine for alleviating dysmenorrhea, endometriosis, and pre-term labor |
| AU2001295359A1 (en) * | 2000-10-30 | 2002-05-15 | University Of Zurich | GnRH analogues for treatment of urinary incontinence |
| GB0221539D0 (en) * | 2002-09-17 | 2002-10-23 | Medical Res Council | Methods of treatment |
| CA2552241C (en) * | 2003-12-30 | 2013-10-01 | Durect Corporation | Co-polymeric devices for controlled release of active agents |
| US20080254086A1 (en) * | 2004-12-23 | 2008-10-16 | Brown James E | Controlled Release Compositions |
| KR20100059863A (ko) * | 2007-09-11 | 2010-06-04 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도 |
| DE102008015104A1 (de) | 2008-03-19 | 2009-09-24 | Basf Coatings Ag | Beschichtungszusammensetzung, Verfahren zu ihrer Herstellung, ihre Verwendung und mit ihr beschichtete Substrate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS563846B2 (enExample) * | 1972-10-12 | 1981-01-27 | ||
| US4218439A (en) * | 1977-07-14 | 1980-08-19 | The Salk Institute For Biological Studies | Peptide which inhibits gonadal function |
| US4256737A (en) * | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| CA1257199A (en) * | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| ATE74009T1 (de) * | 1986-08-11 | 1992-04-15 | American Cyanamid Co | Zusammensetzungen zur parenteralen verabreichung und deren verwendung. |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US5470582A (en) * | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| AUPN366795A0 (en) * | 1995-06-20 | 1995-07-13 | Peptide Technology Limited | Formulation for preventing reproductive function |
-
1995
- 1995-06-20 AU AUPN3667A patent/AUPN366795A0/en not_active Abandoned
-
1996
- 1996-06-20 NZ NZ309697A patent/NZ309697A/xx not_active IP Right Cessation
- 1996-06-20 JP JP50345797A patent/JP4016133B2/ja not_active Expired - Lifetime
- 1996-06-20 DE DE69623652T patent/DE69623652T2/de not_active Expired - Lifetime
- 1996-06-20 DE DE122008000004C patent/DE122008000004I2/de active Active
- 1996-06-20 US US08/981,285 patent/US5925619A/en not_active Expired - Lifetime
- 1996-06-20 DK DK96917292T patent/DK0871467T3/da active
- 1996-06-20 SI SI9630524T patent/SI0871467T1/xx unknown
- 1996-06-20 PT PT96917292T patent/PT871467E/pt unknown
- 1996-06-20 EP EP96917292A patent/EP0871467B1/en not_active Expired - Lifetime
- 1996-06-20 CA CA2225796A patent/CA2225796C/en not_active Expired - Lifetime
- 1996-06-20 WO PCT/AU1996/000370 patent/WO1997000693A1/en not_active Ceased
- 1996-06-20 ES ES96917292T patent/ES2182983T3/es not_active Expired - Lifetime
- 1996-06-20 AT AT96917292T patent/ATE223726T1/de active
- 1996-06-20 AU AU59927/96A patent/AU701837B2/en not_active Expired
- 1996-06-20 CN CNB961948647A patent/CN1145496C/zh not_active Expired - Lifetime
-
1999
- 1999-02-17 US US09/251,411 patent/US6211152B1/en not_active Expired - Lifetime
-
2008
- 2008-01-08 NL NL300330C patent/NL300330I2/nl unknown
- 2008-01-10 FR FR08C0001C patent/FR08C0001I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU701837B2 (en) | 1999-02-04 |
| EP0871467A4 (en) | 2000-07-05 |
| NL300330I1 (nl) | 2008-03-03 |
| CN1188414A (zh) | 1998-07-22 |
| DE122008000004I1 (de) | 2008-04-17 |
| NZ309697A (en) | 1999-11-29 |
| DK0871467T3 (da) | 2002-12-23 |
| JP4016133B2 (ja) | 2007-12-05 |
| CN1145496C (zh) | 2004-04-14 |
| CA2225796A1 (en) | 1997-01-09 |
| AUPN366795A0 (en) | 1995-07-13 |
| HK1014874A1 (en) | 1999-10-08 |
| DE122008000004I2 (de) | 2009-08-06 |
| EP0871467A1 (en) | 1998-10-21 |
| FR08C0001I1 (enExample) | 2008-03-21 |
| PT871467E (pt) | 2002-12-31 |
| JP2001521482A (ja) | 2001-11-06 |
| US5925619A (en) | 1999-07-20 |
| DE69623652T2 (de) | 2003-05-28 |
| NL300330I2 (nl) | 2008-04-01 |
| DE69623652D1 (de) | 2002-10-17 |
| FR08C0001I2 (enExample) | 2009-11-20 |
| EP0871467B1 (en) | 2002-09-11 |
| ES2182983T3 (es) | 2003-03-16 |
| WO1997000693A1 (en) | 1997-01-09 |
| US6211152B1 (en) | 2001-04-03 |
| ATE223726T1 (de) | 2002-09-15 |
| AU5992796A (en) | 1997-01-22 |
| SI0871467T1 (en) | 2003-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6777386B2 (en) | Sustained peptide-release formulation | |
| JP3313113B2 (ja) | 雌馬の排卵制御用生体適合性インプラント | |
| Mylonas et al. | Preparation and evaluation of polyanhydride microspheres containing gonadotropin-releasing hormone (GnRH), for inducing ovulation and spermiation in fish | |
| Gobello | New GnRH analogs in canine reproduction | |
| TWI405578B (zh) | 用以治療荷爾蒙依賴型癌症之起始劑量的ｌｈｒｈ類似物及維持劑量的ｌｈｒｈ拮抗劑之施用法及相對應之藥學套組 | |
| EP1404357B1 (en) | Gonadotropin releasing hormone antagonist in gel-forming concentrations | |
| US5342622A (en) | Subdermal biocompatible implants | |
| US5925619A (en) | Formulation for peptide release | |
| ZA200700068B (en) | Sustained release composition | |
| Korkut et al. | Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. | |
| AU1843899A (en) | Novel formulation for peptide release | |
| AU713413B2 (en) | Sustained peptide-release formulation | |
| HK1014874B (en) | Novel formulation for peptide release | |
| HK1022275B (en) | Sustained peptide-release formulation | |
| Auclair et al. | LHRH and analogues as potential therapy for benign prostatic hyperplasia and hormone-dependent cancers | |
| JPH01500899A (ja) | 生物適合性インプラント |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20160620 |